64Cu-CANF-Comb

N/A

Report date: 2025/11/20 16:02:19
NME

Base Information

Drug Name64Cu-CANF-Comb
Drug Alias Name64Cu-25%-CANF-CombCu[64]-25%-CANF-Comb-II
ClassificationRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionNatriuretic peptide receptor 3 binders
TargetsNatriuretic peptide receptor 3
Therapy Area/IndicationsAtherosclerosisCarotid StenosisCarotid Artery Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesWashington University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of Medicine
Inactive CompaniesN/A
Active IndicationsAtherosclerosisCarotid StenosisCarotid Artery Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A